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laque Burden
ith Composition?
hat Is the Next Question*
teven P. Marso, MD
ansas City, Missouri
therosclerosis is a chronic systemic disease, frequently
eading to vascular morbidity and premature mortality.
lthough atherosclerosis is systemic, plaque rupture, like
olitics, is local. The emergence of innovative plaque
maging modalities has fueled interest in identifying features
f coronary atherosclerosis most likely to be associated with
dverse cardiovascular events. Although several biologically
lausible characteristics of coronary plaque have been pro-
osed, none has been linked with either sudden death or
onfatal myocardial infarction (MI). Plaque severity is 1 of
everal elements that have been studied with intravascular
ltrasound (IVUS).
See page 976
In this issue of the Journal, Hirohata et al. (1) randomized
47 patients with stable angina undergoing percutaneous
oronary intervention to either olmesartan or placebo and
erformed IVUS of a nonculprit coronary artery at baseline
nd 14 months. Treatment allocation was concealed from
he IVUS core laboratory, where coronary arteries were
ystematically interrogated with standard grayscale IVUS
maging techniques. At baseline, the percent atheroma
olume (PAV) was somewhat greater in the olmesartan
roup (43.8% vs. 40.6%, p 0.03). At 14 months there was
ignificant plaque progression in the control group as
easured by total atheroma volume (TAV) (208.8 to 215.9
m3) but no change (neither progression nor regression) in
he olmesartan group. Mean percent change in TAV was
.4% in the control group at follow-up, compared with 0.6%
n the olmesartan group (p  0.016). Similarly, PAV
ncreased 3.1% in control subjects but declined by 0.7% in
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Saint Luke’s Mid America Heart Institute, University of Missouri-
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esearch support from Boston Scientific, The Medicines Company, Volcano Corpo-
ation, and Terumo Medical.he treatment group (p  0.038). These findings suggest a
elationship between olmesartan therapy and delayed coro-
ary atheroma progression.
Change in PAV is often the primary efficacy parameter in
VUS studies not because it is associated with major adverse
ardiac events (MACE) but rather for its minimal variance
nd greater statistical power. It is important to note that
AV (Equation 1) is actually a “composite” IVUS measure-
ent, driven by 2 biological processes: 1) change in coro-
ary plaque volume; and 2) magnitude and direction of
oronary artery remodeling occurring between baseline and
ollow-up measurements. Thus PAV does not solely mea-
ure changes in plaque volume. By contrast, TAV only
easures plaque progression/regression. Although analysis
f plaque progression metrics with MACE in ongoing serial
VUS trials is highly anticipated, to date there are no data
inking either TAV or PAV with observed MACE.
PAV
 (EEMCSALumenCSA)
EEMCSA
 100 [Equation 1]
In the present study there was an approximate 3% increase
n PAV in the control group and a 0.7% decrease in the
lmesartan group. This magnitude of change is consistent with
revious IVUS studies. For example, ASTEROID (A Study
o Evaluate the Effect of Rosuvastatin On Intravascular
ltrasound-Derived Coronary Atheroma Burden) investigators
2) performed IVUS in 349 patients who received intensive statin
herapy with rosuvastatin. Pre-specified IVUS parameters were
AV and change in TAV in the 10-mm subsegment with the
reatest plaque severity. Rosuvastatin was associated with
eductions in low-density lipoprotein cholesterol, PAV
0.98%), and TAV (6.1 mm3). ASTEROID demon-
trated rosuvastatin was associated with modest numerical but
ignificant plaque regression, as opposed to delayed progression
n the present study.
Because no studies to date have directly demonstrated an
ssociation between change in PAV and future risk of
ardiovascular events, it is of interest to determine whether
VUS findings are concordant with cardiovascular outcomes
ssociated with the studied intervention. As shown in
STEROID, there was clear concordance between IVUS
easures of atherosclerosis and clinical benefit of rosuvas-
atin. There are 2 notable examples where clear concordance
etween IVUS surrogates and clinical efficacy of the phar-
acotherapy is lacking: 1) recombinant ApoA-I Milano;
nd 2) cholesterol ester transfer protein inhibition. The
ffect of intravenous recombinant infusion of ApoA-I Mi-
ano (ETC-216) on plaque progression was studied in 57
cute coronary syndromes (ACS) patients (3). The ApoA-I
ilano was given shortly after ACS presentation in 5
eekly treatments and was associated with reductions of
.06% in PAV and 4.2% in TAV compared with baseline.
espite these findings, ApoA-I Milano has not been fully
eveloped, for reasons that are not entirely clear. Demon-
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Plaque Burden With Composition? March 9, 2010:983–5tration of concordance between IVUS and the clinical
fficacy of ApoA-1 Milano might be prolonged, because
linical development stalled shortly after Pfizer (New York,
ew York) acquired ETC-216 (4). Although retaining
ntellectual property rights to this compound, Pfizer has
ivested other significant lipid regulatory molecules, leaving
uch ambiguity on future clinical development of high-
ensity lipoprotein cholesterol therapies.
Torcetrapib, a cholesterol ester transfer protein inhibitor,
as studied in ILLUMINATE (Investigation of Lipid Level
anagement to Understand its Impact in Atherosclerotic
vents) (cardiovascular outcomes) and ILLUSTRATE (In-
estigation of Lipid Level management using coronary Ultra-
ound To assess Reduction of Atherosclerosis by ceTp inhi-
ition and HDL Elevation) (IVUS) (5). Over 15,000 patients
ere randomized to torcetrapib or placebo in ILLUMINATE.
lthough high-density lipoprotein cholesterol levels in-
reased by more than 60% in the torcetrapib arm, the trial
as terminated prematurely due to an increased risk of
eath and cardiac events in these patients. ILLUSTRATE
6) randomized 910 patients to atorvastatin and torcetrapib
r atorvastatin monotherapy. Serial IVUS findings showed
hat PAV increased by 0.19% in the control group and by
.12% in the combination group (p  0.72). By contrast,
here was significant plaque regression in the torcetrapib
roup as evaluated by a reduction in normalized atheroma
olume (9.5 mm3 torcetrapib vs. 6.3 mm3 control, p 
.02). Thus the IVUS findings were not clearly concordant
ith the safety signal seen in ILLUSTRATE, suggesting
hat the use of IVUS end points as surrogate markers for
therosclerosis is a complex issue. Certainly, although there
as no beneficial effect on PAV, torcetrapib led to plaque
egression as measured by atheroma volume. It is possible
hat off-target effects of torcetrapib might have accounted
or the cardiovascular safety signal, but of course IVUS
ould not be expected to reveal these.
Progression of atherosclerosis has also been evaluated in
lucose-lowering treatments. The PERISCOPE (Pioglita-
one Effect on Regression of Intravascular Sonographic
oronary Obstruction Prospective Evaluation) trial (7)
andomized 543 individuals with type 2 diabetes to the
aximum tolerated dosage of glimepiride or pioglitazone.
epeat IVUS was available in 360 patients. The main
utcome measure, PAV, increased by 0.73% in the
limepiride arm and decreased 0.16% in the pioglitazone
rm (p  0.002). Although the cardiovascular effects of
lucose-lowering are yet unknown, pioglitazone was asso-
iated with a reduction in death and MI in PROactive
PROspective pioglitAzone Clinical Trial In macro-
ascular Events) (8). A recent meta-analysis (9) also suggests
mprovement in cardiovascular outcomes associated with ag-
ressive treatment. Thus, results from the PERISCOPE trial
re mostly concordant with the perceived benefit of pioglita-
one on MACE.
The salient issue is whether plaque quantity, composi-ion, eccentricity, vessel remodeling, or a combination of ihese will be linked with risk for MACE. Innovation in
maging platforms now makes it clinically feasible to iden-
ify compositional elements of coronary atherosclerosis.
xamples of emerging platforms include optical coherence
omography, near-infrared spectroscopy, and various IVUS
latforms, including integrated backscatter, Virtual Histol-
gy (VH) (Volcano Corp., Rancho Cordova, California)
nd wavelet analysis. VH-IVUS uses the mathematical
echnique of autoregressive modeling to classify IVUS-
adiofrequency data into 1 of 4 color-coded plaque compo-
ents: 1) fibrous (green); 2) fibrofatty (light green); 3) dense
alcium (white); and 4) necrotic core (red). Expert consen-
us guidelines for analyzing and interpreting VH-IVUS
mages have been published (10). Based on composition
nalysis, this platform can be extended to define specific
laque phenotypes, including adaptive and pathological
ntimal thickening, thin cap fibroatheroma (TCFA), fibro-
theroma, and fibrocalcific. Of these, TCFA is widely
elieved to be the leading vulnerable plaque phenotype.
lthough a consensus description does not yet exist, likely
haracteristics of VH-TCFA include plaque thickness
600 m, confluent luminal necrotic core, and no fibrous
ap. Although an unresolved issue, linking plaque severity
ith composition might also add important prognostic
nformation. Thus a minimal plaque burden threshold
approximately 50%) with TCFA is also of interest. Prior
VUS studies have demonstrated symptomatic future plaque
upture to be associated with relatively greater plaque
urden and smaller lumen size (11).
Confluent necrotic core is a key element of TCFA and
laque rupture (12). Recent studies have suggested that the
uantity of necrotic core might be modifiable with pharma-
otherapy. In 330 patients randomized to the lipoprotein-
ssociated phospholipase A2 (Lp-PLA2) inhibitor darap-
adib (160 mg daily) or placebo, Serruys et al. (13) found a
eduction in necrotic core volume with darapladib at 12
onths (0.5  13.9 mm3, p  0.71) compared with a
ignificant increase in placebo-treated subjects (4.5  17.9
m3, p 0.009). The intergroup difference was5.2 mm3,
 0.012. Although TAV decreased in both groups
ompared with baseline, the difference between groups was
ot significant. Although they suggest that meaningful
hanges in composition might occur without measured
ifferences in plaque severity, the clinical utility of these
ndings is unknown.
Several studies have recently been published that have
ttempted to link TCFA with cardiovascular risk. An
ssociation between the frequency of VH-TCFA and Fra-
ingham Risk Score (14) as well as duration of diabetes
15) has been demonstrated, both of which are associated with
reater cardiovascular risk. In over 300 ACS and stable angina
atients who underwent VH-IVUS, culprit lesions from the
CS cohort were significantly more likely to be VH-TCFA
ompared with the stable angina cohort (16). Although it
hould be noted that these cross-sectional studies all fall short
n linking TCFA as a potential vulnerable plaque phenotype
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March 9, 2010:983–5 Plaque Burden With Composition?ith risk of future MACE, the long-awaited results of
ROSPECT (Providing Regional Observations to Study
redictors of Events in the Coronary Tree) (17)—recently
resented at the Transcatheter Cardiovascular Therapeutics
009 conference—provide the first insights on atheroscle-
osis progression and secondary events in an ACS popu-
ation. The PROSPECT investigators enrolled 697 ACS
atients (66% non–ST-segment elevation MI, 30% ST-
egment elevation MI, 4% unstable angina) who mostly
nderwent 3-vessel VH-IVUS at baseline. Imaging stud-
es were repeated over the next 5 years in patients with
epeat events. In nearly 2,700 lesions identified at base-
ine, 13% contained necrotic core and 22.4% were clas-
ified as VH-TCFA, defined as 10% necrotic core with-
ut a visible fibrous cap at the lumen. During median
ollow-up of 3.4 years, 11.6% of patients developed MACE
nvolving a nonculprit lesion (the primary end point),
lthough 12.4% had MACE involving a culprit lesion.
esions classified as VH-TCFA were associated with the
reatest risk of MACE in a nonculprit lesion (hazard ratio:
.84, 95% confidence interval: 2.22 to 6.65, p  0.0001).
he VH-TCFA lesions combined with 70% plaque
urden were associated with the greatest risk of MACE in
nonculprit lesion (hazard ratio: 10.8, 95% confidence
nterval: 5.5 to 21.0, p  0.0001). These very preliminary
esults suggest that grayscale IVUS coupled with composi-
ional analysis might be a powerful tool to localize high-risk
egions for future MI. Undoubtedly, there will be interest in
laque-modifying interventions designed to lower individ-
al risk for mortal and morbid cardiovascular events.
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